On Monday biotech corporation Moderna Inc. announced that its new Covid-19 vaccine has been 94.5% effective in preventing infection in tests so far. On Wednesday, Pfizer and BioNTech announced results from their late-stage vaccine trial, saying that theirs was 95% effective and had no serious side effects. The results of both trials add to the growing confidence that vaccines could help end the pandemic in a matter of months and restore a sense of normalcy to everyone’s lives.
There is widespread agreement that healthcare workers should be a high priority in getting the vaccine first. Epidemiologists say workers in essential industries, people with certain medical conditions and people age 65 and older would likely also be among the early recipients.
Much, but not all, of the funding for the development of the Moderna vaccine came from taxpayers. Moderna received nearly $2.5 billion from the federal government -- reinforcing the belief among consumer and health advocates that any taxpayer-funded vaccines or treatments for COVID-19 must be accessible, affordable, and available to all who need them.
The Alliance is urging Congress to pass the Make Medications Affordable by Preventing Pandemic Price-gouging (MMAPPP) Act, which would prohibit monopoly control over drug prices and require the federal government to mandate affordable prices for treatments and vaccines developed with taxpayer dollars. Representatives Jan Schakowsky (IL), Francis Rooney (FL), Lloyd Doggett (TX), Rosa DeLauro (CT), and Peter DeFazio (OR) introduced the legislation.
“The news of there being two highly effective vaccines is very promising,” said Robert Roach, Jr., President of the Alliance. “However this and any treatment that we fund with our tax dollars must be available and affordable for all who need it. Congress must also pass the MMAPPP Act to ensure this happens for drugs to treat COVID-19 or other diseases.”